IP Library Granted Patent US 11,344,617
Granted Patent B2
US 11,344,617 · App. 16/769,820 · Granted May 31, 2022

Liquid vaccines of live enveloped viruses

Inventors: Paul Vermeij (St. Anthonis, NL); Edwin Kets (Heilig Landstichting, NL); Chris Dirks (Gemert, NL); Martin Piest (Afferden, NL)
Assignee: Intervet Inc.
A61K39/155A61K9/08A61K39/12A61K39/175A61K39/215A61K39/245A61K47/10A61K47/186A61K47/22A61K47/26C12N7/00A61K2039/525A61K2039/54A61K2039/543C12N2710/16034C12N2760/00034C12N2760/18034C12N2760/18434C12N2760/18634C12N2770/20034
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,344,617
App. No.
16/769,820
Granted
May 31, 2022
Kind
B2
Abstract

The present invention describes a liquid vaccine composition of a live enveloped virus and a pharmaceutically acceptable carrier, whereby the carrier is a natural deep-eutectic solvent (NADES), and the vaccine has a water activity of less than about 0.8. The NADES provides a stabilisation of the sensitive virus for prolonged time and at ambient temperature. In general, the liquid vaccine compositions according to the invention, in different compositions for the various enveloped viruses, show remarkable capabilities of stabilisation. This overcomes the need for lyophilisation, a great economic benefit. Also the liquid nature of the vaccines facilitates administration to human or animal targets.

Claims (13)

1. A liquid vaccine composition comprising a live enveloped virus and a pharmaceutically acceptable carrier; wherein the carrier is a natural deep-eutectic solvent (NADES), the vaccine has a water activity between about 0.8 and about 0.1, and wherein the water content in said composition is less than about 50% w/v.

2. The liquid vaccine composition of claim 1 , wherein the NADES comprises an organic salt and a polyol.

3. The liquid vaccine composition of claim 2 , wherein the organic salt is selected from the group consisting of betaine, proline, carnitine, and choline.

4. The liquid vaccine composition of claim 2 , wherein the polyol is a sugar or a sugar-alcohol.

5. The liquid vaccine composition of claim 2 , wherein the polyol is selected from the group consisting of sucrose, glycerol, xylitol, and sorbitol.

6. The liquid vaccine composition of claim 1 , wherein the enveloped virus has an RNA genome.

7. A method of preparing the liquid vaccine composition of claim 1 , comprising the steps of:

a. preparing the NADES, and

b. admixing the NADES and a composition comprising the live enveloped viruses.

8. A method of vaccinating a human or animal target, comprising administering the liquid vaccine composition made by the method of claim 7 .

9. A kit comprising at least two containers, wherein one container comprises the liquid vaccine composition of claim 1 and one container comprises a liquid diluent.

10. A method of vaccinating a human or animal target, comprising administering the liquid vaccine composition mixed with the diluent that both came in the kit of claim 9 .

11. A method of vaccinating a human or animal target caused by a pathogenic form of the live enveloped virus, comprising administering the liquid vaccine composition of claim 1 .

Assignments (2)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2020
From: VERMEIJ, PAUL; KETS, EDWIN P W; DIRKS, CHRIS; PIEST, MARTIN
To: INTERVET INC.
Reel/Frame 052840/0646 →
Priority Claims (1)
EP 17210395 · Dec 22, 2017 · regional
Continuity (1)
Related Publication 20200368346A1 · Nov 26, 2020